This document has been translated from the Japanese original for reference purposes only.

In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.



Company name: Modalis Therapeutics Corporation Stock exchange listing: Tokyo Stock Exchange

Code number: 4883

URL: https://www.modalistx.com/en/ Representative: Haruhiko Morita

Notice Regarding Change of the Executive Officer

1. Newly appointed Executive Officer (as of October 1, 2025)

Name	New position	Former position
Dr. Yuanbo Qin	VP, Neuromuscular Diseases	Senior Director, Neuromuscular Diseases
Dr. Seth Levy	VP, Manufacturing	Senior Director, Process Development

For more info, please visit our website (www.modalistx.com)